Humana Inc. Reports Mixed Financial Results for Fourth Quarter 2024 and Sets Guidance for 2025
1. Overview of Financial Performance
On February 11, 2025, Humana Inc. (NYSE: HUM) announced its consolidated financial results for the fourth quarter of 2024 (4Q24) and provided guidance for the full year 2025 (FY 2025). The results exhibited a notable decline in pretax income and net earnings per share compared to the same period last year, reflecting ongoing challenges in the healthcare market. Humana's President and CEO, Jim Rechtin, expressed confidence in the company's long-term strategy, asserting that 2025 would be pivotal for restoring normalized margins.
2. Fourth Quarter Results
For 4Q24, Humana reported a consolidated pretax loss of $862 million, compared to a loss of $591 million in 4Q23. The company's GAAP net loss per share was ($5.76), a significant decline from ($4.42) in the prior year. Adjusted (non-GAAP) results showed a loss of $296 million for the quarter, contrasting with a profit of $79 million in 4Q23.
Key Financial Metrics
| Metric | 4Q24 | 4Q23 |
|---|---|---|
| Consolidated Pretax Results | ($862 million) | ($591 million) |
| GAAP EPS | ($5.76) | ($4.42) |
| Adjusted Loss | ($296 million) | $79 million |
| Adjusted EPS | ($2.16) | ($0.11) |
The decline in earnings was influenced by various factors, including impairment charges of $200 million and an exit from the employer group commercial medical products business, which negatively impacted revenues and margins.
3. Full Year 2024 Overview
For the entire fiscal year 2024, Humana reported consolidated pretax income of $1.721 billion, down from $3.383 billion in FY 2023. The company’s GAAP net earnings per share for FY 2024 came in at $9.98, a decrease from $20.00 in the previous year.
Full Year Financial Highlights
| Metric | FY 2024 | FY 2023 |
|---|---|---|
| Consolidated Pretax Income | $1.721 billion | $3.383 billion |
| GAAP EPS | $9.98 | $20.00 |
| Adjusted EPS | $16.21 | $26.09 |
These numbers highlight the challenges Humana faced through the year, particularly in managing costs and maintaining profitability amid a shifting healthcare landscape.
4. Guidance for FY 2025
Looking ahead, Humana has provided guidance for FY 2025, projecting a GAAP EPS of approximately $15.88 and an adjusted EPS of around $16.25. This represents a strategic effort to stabilize earnings following a turbulent 2024.
Projected Earnings Guidance
| Metric | FY 2025 Guidance | FY 2024 Actual |
|---|---|---|
| GAAP EPS | ~$15.88 | $9.98 |
| Adjusted EPS | ~$16.25 | $16.21 |
Rechtin stated, “We are confident in our long-term strategy and 2025 will be a critical step in returning to compelling, normalized margins,” indicating a proactive approach to regaining financial stability.
5. Market Reactions and Future Considerations
Humana's results have elicited mixed reactions from the market, as investors weigh the company's ability to rebound from recent losses against the backdrop of a challenging healthcare environment. The upcoming year will be crucial for Humana, especially in navigating regulatory pressures and achieving operational efficiencies.
The company’s focus on its Medicare initiatives and the performance of its CenterWell business will be pivotal in driving revenue growth and improving margins in 2025.
6. Conclusion
Humana Inc.'s fourth-quarter results present a complex picture of a company grappling with significant financial challenges while laying the groundwork for recovery in 2025. With projected earnings improvements and a commitment to strategic initiatives, investors will be keenly observing Humana's progress in the coming quarters as it aims to restore profitability and enhance shareholder value.
For further details, Humana will host a conference call at 9:00 a.m. Eastern Time to discuss these results and answer analyst questions. The full earnings release is available on Humana’s Investor Relations site.
